233 related articles for article (PubMed ID: 34321273)
1. Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors.
Tenesaca S; Vasquez M; Alvarez M; Otano I; Fernandez-Sendin M; Di Trani CA; Ardaiz N; Gomar C; Bella A; Aranda F; Medina-Echeverz J; Melero I; Berraondo P
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34321273
[TBL] [Abstract][Full Text] [Related]
2. Vaccination with recombinant modified vaccinia virus Ankara prevents the onset of intestinal allergy in mice.
Bohnen C; Wangorsch A; Schülke S; Nakajima-Adachi H; Hachimura S; Burggraf M; Süzer Y; Schwantes A; Sutter G; Waibler Z; Reese G; Toda M; Scheurer S; Vieths S
Allergy; 2013 Aug; 68(8):1021-8. PubMed ID: 23909913
[TBL] [Abstract][Full Text] [Related]
3. Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens.
García-Arriaza J; Gómez CE; Sorzano CÓ; Esteban M
J Virol; 2014 Mar; 88(6):3392-410. PubMed ID: 24390336
[TBL] [Abstract][Full Text] [Related]
4. Intraperitoneal administration of a modified vaccinia virus Ankara confers single-chain interleukin-12 expression to the omentum and achieves immune-mediated efficacy against peritoneal carcinomatosis.
Bella Á; Arrizabalaga L; Di Trani CA; Gonzalez-Gomariz J; Gomar C; Russo-Cabrera JS; Olivera I; Cirella A; Fernandez-Sendin M; Alvarez M; Teijeira A; Atay C; Medina-Echeverz J; Hinterberger M; Hochrein H; Melero I; Berraondo P; Aranda F
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37918917
[TBL] [Abstract][Full Text] [Related]
5. Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.
Garber DA; O'Mara LA; Zhao J; Gangadhara S; An I; Feinberg MB
PLoS One; 2009; 4(5):e5445. PubMed ID: 19421328
[TBL] [Abstract][Full Text] [Related]
6. Removal of the C6 Vaccinia Virus Interferon-β Inhibitor in the Hepatitis C Vaccine Candidate MVA-HCV Elicited in Mice High Immunogenicity in Spite of Reduced Host Gene Expression.
Marín MQ; Pérez P; Gómez CE; Sorzano CÓS; Esteban M; García-Arriaza J
Viruses; 2018 Aug; 10(8):. PubMed ID: 30096846
[TBL] [Abstract][Full Text] [Related]
7. Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways.
García-Arriaza J; Arnáez P; Gómez CE; Sorzano CÓ; Esteban M
PLoS One; 2013; 8(6):e66894. PubMed ID: 23826170
[TBL] [Abstract][Full Text] [Related]
8. Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model.
Remy-Ziller C; Thioudellet C; Hortelano J; Gantzer M; Nourtier V; Claudepierre MC; Sansas B; Préville X; Bendjama K; Quemeneur E; Rittner K
Hum Vaccin Immunother; 2018 Jan; 14(1):140-145. PubMed ID: 28925793
[TBL] [Abstract][Full Text] [Related]
9. Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes.
Gherardi MM; Nájera JL; Pérez-Jiménez E; Guerra S; García-Sastre A; Esteban M
J Virol; 2003 Jun; 77(12):7048-57. PubMed ID: 12768024
[TBL] [Abstract][Full Text] [Related]
10. Type I Interferon Promotes Humoral Immunity in Viral Vector Vaccination.
Zhong C; Liu F; Hajnik RJ; Yao L; Chen K; Wang M; Liang Y; Sun J; Soong L; Hou W; Hu H
J Virol; 2021 Oct; 95(22):e0092521. PubMed ID: 34495698
[TBL] [Abstract][Full Text] [Related]
11. Efficient Induction of Cytotoxic T Cells by Viral Vector Vaccination Requires STING-Dependent DC Functions.
Barnowski C; Ciupka G; Tao R; Jin L; Busch DH; Tao S; Drexler I
Front Immunol; 2020; 11():1458. PubMed ID: 32765505
[TBL] [Abstract][Full Text] [Related]
12. Modified vaccinia virus Ankara induces Toll-like receptor-independent type I interferon responses.
Waibler Z; Anzaghe M; Ludwig H; Akira S; Weiss S; Sutter G; Kalinke U
J Virol; 2007 Nov; 81(22):12102-10. PubMed ID: 17855554
[TBL] [Abstract][Full Text] [Related]
13. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
14. Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV.
Marín MQ; Pérez P; Ljungberg K; Sorzano CÓS; Gómez CE; Liljeström P; Esteban M; García-Arriaza J
J Virol; 2019 Apr; 93(7):. PubMed ID: 30674625
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cells are preferentially targeted among hematolymphocytes by Modified Vaccinia Virus Ankara and play a key role in the induction of virus-specific T cell responses in vivo.
Liu L; Chavan R; Feinberg MB
BMC Immunol; 2008 Apr; 9():15. PubMed ID: 18412969
[TBL] [Abstract][Full Text] [Related]
16. Modified Vaccinia Virus Ankara Can Induce Optimal CD8
Wong YC; Croft S; Smith SA; Lin LCW; Cukalac T; La Gruta NL; Drexler I; Tscharke DC
J Virol; 2019 Nov; 93(21):. PubMed ID: 31375596
[TBL] [Abstract][Full Text] [Related]
17. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
[TBL] [Abstract][Full Text] [Related]
18. Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model.
Ishizaki H; Manuel ER; Song GY; Srivastava T; Sun S; Diamond DJ; Ellenhorn JD
Cancer Immunol Immunother; 2011 Jan; 60(1):99-109. PubMed ID: 20960189
[TBL] [Abstract][Full Text] [Related]
19. Recombinant modified vaccinia virus Ankara generating excess early double-stranded RNA transiently activates protein kinase R and triggers enhanced innate immune responses.
Wolferstätter M; Schweneker M; Späth M; Lukassen S; Klingenberg M; Brinkmann K; Wielert U; Lauterbach H; Hochrein H; Chaplin P; Suter M; Hausmann J
J Virol; 2014 Dec; 88(24):14396-411. PubMed ID: 25297997
[TBL] [Abstract][Full Text] [Related]
20. Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses.
Hodge JW; Poole DJ; Aarts WM; Gómez Yafal A; Gritz L; Schlom J
Cancer Res; 2003 Nov; 63(22):7942-9. PubMed ID: 14633725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
